浙江醫藥(600216.SH):擬推第二期限制性股票激勵計劃
格隆匯12月30日丨浙江醫藥(600216.SH)公佈第二期限制性股票激勵計劃(草案),該激勵計劃擬向激勵對象授予合計不超過682.75萬股公司限制性股票,約佔該激勵計劃草案公吿時公司股本總額96,512.80萬股的0.71%。
截至激勵計劃草案公吿當日,公司從二級市場上回購的公司A股普通股股票合計6,827,500股,全部作為實施公司該激勵計劃的股票來源。
該激勵計劃限制性股票的授予價格參照公司從二級市場回購股票的平均價格確定,為8.78元/股。
該激勵計劃授予的激勵對象總人數為505人,激勵對象包括公司董事、高級管理人員及核心業務(技術)人員,不含獨立董事、監事、單獨或合計持股5%以上的股東或實際控制人及其配偶、父母、子女。
該激勵計劃的有效期自限制性股票授予登記完成之日起至所有限制性股票解除限售或回購註銷完畢之日止,不超過36個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.